Vaccines against tuberculosis: where are we and where do we need to go?

Ottenhoff TH, Kaufmann SH. · 2012

Read Vaccines against tuberculosis: where are we and where do we need to go? by Ottenhoff TH, Kaufmann SH. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3349743.txt.

Introduction

Ottenhoff and Kaufmann reviewed the search for a better tuberculosis vaccine, in work published in 2012. The only vaccine in use, BCG, dates from the early twentieth century. It shields young children from the worst forms of the disease but works patchily against the adult lung form, which is the form that keeps the disease spreading.

The review surveys what might come next: booster shots built on viruses, reworked BCG strains, and subunit vaccines meant to top up or replace the first dose. The authors weigh the lack of clear immune markers for protection and the slow, hard task of proving that a new vaccine works in large trials.

Catalog record

CREATOROttenhoff TH, Kaufmann SH.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE88 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3349743

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? By Tom H M Ottenhoff, Stefan H E Kaufmann, Chetan E Chitnis Published in: PLoS Pathogens DOI: 10.1371/journal.ppat.1002607 ABSTRACT Abstract In this review we discuss recent progress in the development, testing, and clinical evaluation of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has been made in TB vaccine research and development: from a pipeline virtually empty of new TB candidate vaccines in the early 1990s, to an era in which a dozen novel TB vaccine candidates have been and are being evaluated in human clinical trials. In addition, innovative approaches are being pursued to further improve existing vaccines, as well as discover new ones. Thus, there is good reason for optimism in the field of TB vaccines that it will be possible to develop better vaccines than BCG, which is still the only vaccine available against TB. INTRODUCTION It has proven challenging to develop vaccines against pathogens whose control depends on the cellular immune response. Tuberculosis (TB) is no exception. Most successful vaccines today target pathogens against which humoral immunity suffices to achieve protection and often sterile eradication. But TB vaccines need to drive primarily the cellular arm of the immune system. Mycobacterium tuberculosis (Mtb), the intracellular pathogen that causes TB, was discovered in 1882 by Robert Koch (Nobel Laureate in 1905) and is responsible for more human deaths than any other single pathogen today [1]–[3]. The combination with HIV co-infection, which dramatically compromises host resistance to TB, leads to high disease prevalence in affected endemic populations. Currently, each year more than 1.5 million people die of TB, and more than 9 million newly develop TB [4]. This dire situation is further compromised by the increasing prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains [5], and the more recent occurrence of TDR (totally drug-resistant) Mtb strains, which are virtually untreatable [6]. TB, known also as the white plague, has been around for millennia. Early last century, hopes were that TB could be conquered by vaccination with the newly developed M. bovis BCG vaccine, isolated by and named after Calmette and Guérin in Lille, France [7]. These hopes were further boosted by the development of the first anti-tuberculous drugs during WWII by Selman Waksman (Nobel Laureate in 1952), who discovered that streptomycin was bacteriostatic for Mtb [8]. Initially, treatment with streptomycin appeared highly efficacious, but the tide turned when drug resistance rapidly developed, an early testimony of Mtb's ability to acquire drug resistance when treated by single antibiotics. Despite this early writing on the wall, the misconception that TB could be conquered by antibiotics and BCG vaccination led to complacency for several decades. This situation dramatically changed only in the early 1990s, when the World Health Organization (WHO) declared TB a global emergency. From that time onwards TB scientists, who had been focusing much of their efforts on other areas of research and development due to a lack of interest in and funding for TB, were able to reorient efforts and initiate significant activities in the study of TB [9]. Soon, researchers determined Mtb's genome sequence [10], and began to dissect TB's immunology and cell biology. Although in most cases, TB can be treated successfully with multidrug combinations of antibiotics (except for MDR-, XDR-, and TDR-TB), treating TB cases is clearly insufficient to interrupt disease transmission in highly endemic populations, because an active TB case will typically infect some 10 to 15 contacts [4] per year. Better preventive measures that block Mtb transmission need to be developed, including vaccines that prevent establishment of Mtb infection in the susceptible human host (infection-blocking vaccines), or alternatively, vaccines that prevent progression of established infection towards active TB disease (disease-progression-blocking vaccines). The only available vaccine against TB today remains the almost one-century-old BCG. It is routinely administered to infants in many countries worldwide and provides significant protection against severe forms of TB, mostly disseminating and meningeal forms. However, the protective efficacy of BCG against pulmonary TB in adults is inconsistent and incomplete, and BCG vaccination campaigns have had little impact on the occurrence of pulmonary TB, which represents the transmissible form of this disease. It is still unclear why the protective effect of neonatal or early-age BCG vaccination often begins to wane in early adolescence, at least in TB-endemic areas, as will be discussed further below. Nevertheless, in a North American study, BCG's protective efficacy was found to last for over 50 years [11], thus pointing to the importance of possible environmental modulators (co-infections, co-morbidity, nutrition, genetics, TB exposure intensity, etc.; see below). Another issue of concern that compromises BCG's utility is that infants with HIV have an increased risk of developing disseminated BCG-osis [12], bearing similarities to individuals with genetic deficiencies in the interleukin (IL)-12/IL-23/interferon-gamma (IFNγ)/signal transducer and activator of transcription (STAT)1 pathway [13], [14]. This implies that TB vaccines need to be developed that not only have a superior ability to induce protective immunity against TB, but also have a better safety profile compared to BCG [12], [15]. There has been significant progress in TB research over the last 20 years. From a pipeline empty of new TB vaccine candidates in the early 1990s, more than 12 novel TB vaccine candidates now have been or are being evaluated in clinical trials in humans. Moreover, many new approaches and strategies are under evaluation for further improvement of these and other vaccines. This raises hope that vaccines can be developed which are better than BCG. It will be critical to mobilize the needed funding, political, and supranational support, and increase public awareness of the pressing needs in TB in order to step up efforts towards controlling this resilient disease. The recent declaration by the European Parliament to support TB vaccine research and development (http://www.tbvi.eu/news-agenda/news/news-message/eu-parlement-discusses-the-importance-of-tb-vaccines.html) is a laudable step in this direction. TB INFECTION CONTROL Infection with Mtb does not necessarily lead to TB disease. Only 3%–10% of immunocompetent individuals that are infected will progress towards active disease during their life-time [16]. It is unknown if—and what proportion of—infected individuals are able to possibly achieve complete or “sterile" eradication of bacteria following primary pulmonary infection. Existing yet indirect evidence suggests that this may be the case and could be dependent on innate rather than adaptive immune defense mechanisms, as persons have been described who despite high intensity exposure—and thus likely infection—remain tuberculin skin test (TST)-negative and do not develop disease [17], [18]. The TST is a classical indicator of delayed type hypersensitivity-dependent T-cell activity towards Mtb antigens in the case of previous contact. TST surveys suggest that around one-third of the world's population, amounting for over 2.2 billion people, is infected with Mtb [4]. Although >90% are able to contain infection in a latent or subclinical stage, this huge reservoir of latently infected individuals fuels the high numbers of new active TB cases [19]. The development of active TB is dramatically accelerated by co-infection with HIV, which increases Mtb reactivation rates from 3%–10% per life-time to 5%–10% per life-year [20]. Latent Mtb infection also poses iatrogenic clinical challenges, due to increases in TB reactivation following administration of biologicals, such as tumor necrosis factor-alpha (TNFα)/IL-12/IL-23 blockers in

Read the complete text